Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 130 of the 131 references it cites were found in a registry or an index; 39 of the 112 sources its claims cite were checked for support.

Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer

Open access

Abstract

Drug resistance is perhaps the greatest challenge in improving outcomes for cancer patients undergoing treatment with targeted therapies. It is becoming clear that “persisters,” a subpopulation of drug-tolerant cells found in cancer populations, play a critical role in the development of drug resistance. Persisters are able to maintain viability under therapy but are typically slow cycling or dormant. These cells do not harbor classic drug resistance driver alterations, and their partial resistance phenotype is transient and reversible upon removal of the drug. In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy. Thus, eliminating persister cells will be crucial to improve outcomes for cancer patients. Using lung cancer targeted therapies as a primary paradigm, this review will give an overview of the characteristics of drug-tolerant persister cells, mechanisms associated with drug tolerance, and potential therapeutic opportunities to target this persister cell population in tumors.

Overview

CoChat Summary

TL;DR

This review argues that drug-tolerant persister cells survive targeted therapy without bona fide resistance mutations, are often slow-cycling/dormant, and can serve as a reservoir from which acquired resistance evolves. It summarizes mechanisms of tolerance and potential therapeutic vulnerabilities, using lung cancer targeted therapies as the primary paradigm.

Key findings

  • In the founding cancer persister study, ~0.3% of PC9 EGFR-mutant NSCLC cells survived lethal-dose erlotinib as slowly cycling drug-tolerant persisters; upon drug removal, expanded persisters reverted to a drug-sensitive state.
  • Acquired resistance can evolve from persisters: in PC9 pools treated with gefitinib, 5–10% developed rapid EGFR T790M resistance as early as 2 weeks, while most underwent initial response followed by slow expansion of drug-tolerant cells and later full resistance.
  • Clinical resistance mechanisms include secondary mutations such as EGFR T790M, bypass signaling such as MET activation in 5–10% of EGFR TKI-resistant lung cancers, and lineage transformation in 5–15% of EGFR-mutant lung cancer patients with acquired resistance.
  • Persister mechanisms reviewed include epigenetic/chromatin reprogramming, bypass/alternative signaling, apoptosis suppression, metabolic reprogramming, tumor microenvironment interactions, and adaptive mutagenesis; clinical minimal residual disease is the closest analogue.

Methods

  • Narrative review of in vitro, in vivo, and clinical studies on drug-tolerant persister cells, focused on targeted therapies for solid malignancies and using lung cancer as the primary paradigm.
  • Synthesizes mechanistic studies and includes Table 1 cataloging tumor type, target oncogene, targeted therapy, model system, mechanism of drug tolerance, and susceptibility for each study.
  • No systematic review, meta-analysis, or primary experimental methods are reported.

Limitations

  • The paper states that understanding clinical persisters is limited by difficulty accessing tumor tissue at minimal residual disease, that molecular signatures indicating whether relapsed tumors passed through a persister state are undefined, and that the true extent of relapse from persister evolution versus pre-existing resistant clones remains unknown.
  • The paper states that tumor microenvironment contributions cannot be addressed well by in vitro models or in vivo studies using immunocompromised mice, and that future work should prioritize on-treatment biopsies.
  • Evident from the text: this is a narrative review without systematic search or quantitative synthesis, so conclusions depend on the selected literature and model systems discussed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/cancers13112666

Cites

130 of 130 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Resistance to targeted cancer therapies. Drug resistance can occur at the time of initial therapy (primary resistance) or develop after initial therapy response (acquired resistance). (A) Primary resistance may be due to intrinsic resistance resulting from ineffective targeting of the oncogenic driver such that oncogenic signaling is not suppressed (for instance, activating KRAS mutations confer resistance to EGFR targeted therapy). Alternatively, in adaptive resistance, cells rapidly rewire oncogenic signaling after initial suppression such that therapy does not induce death in the bulk of tumor cells. (B) In acquired drug resistance, disease relapse after initial therapy response may be driven by Darwinian selection of resistant clones that exist before treatment and expand under the selective pressure of therapy (for instance, rare T790M+ clones in some EGFR-mutant lung cancers), or evolution of drug-tolerant “persister” cells that acquire resistance mechanisms during the course of therapy.
Figure 1 Resistance to targeted cancer therapies. Drug resistance can occur at the time of initial therapy (primary resistance) or develop after initial therapy response (acquired resistance). (A) Primary resistance may be due to intrinsic resistance resulting from ineffective targeting of the oncogenic driver such that oncogenic signaling is not suppressed (for instance, activating KRAS mutations confer resistance to EGFR targeted therapy). Alternatively, in adaptive resistance, cells rapidly rewire oncogenic signaling after initial suppression such that therapy does not induce death in the bulk of tumor cells. (B) In acquired drug resistance, disease relapse after initial therapy response may be driven by Darwinian selection of resistant clones that exist before treatment and expand under the selective pressure of therapy (for instance, rare T790M+ clones in some EGFR-mutant lung cancers), or evolution of drug-tolerant “persister” cells that acquire resistance mechanisms during the course of therapy.CC BY · PubMed Central
Figure 2 Conceptual similarities between bacterial and cancer persisters. (A) Survival curves depict bacterial state trajectories during exposure to antibiotics. Sensitive bacterial populations (blue) are eliminated by antibiotic treatment, whereas resistant bacteria (dark gray) continue to proliferate in the presence of antibiotic. Persister bacteria (orange) can survive during antibiotic exposure, but upon drug withdrawal, repopulate rapidly, proliferating sensitive bacterial populations. (B) Prototypical survival curve illustrating the emergence and reversibility of drug-tolerant cancer cells from a primarily drug-sensitive population. Treatment of heterogenous tumor cell populations with targeted therapy eliminates sensitive clones, revealing a subpopulation of so-called “drug-tolerant persister cells” (DTPs). A hallmark of the persister state is reversibility upon withdrawal of drug, resulting in re-establishment of a mixed population of sensitive and drug-tolerant cells.
Figure 2 Conceptual similarities between bacterial and cancer persisters. (A) Survival curves depict bacterial state trajectories during exposure to antibiotics. Sensitive bacterial populations (blue) are eliminated by antibiotic treatment, whereas resistant bacteria (dark gray) continue to proliferate in the presence of antibiotic. Persister bacteria (orange) can survive during antibiotic exposure, but upon drug withdrawal, repopulate rapidly, proliferating sensitive bacterial populations. (B) Prototypical survival curve illustrating the emergence and reversibility of drug-tolerant cancer cells from a primarily drug-sensitive population. Treatment of heterogenous tumor cell populations with targeted therapy eliminates sensitive clones, revealing a subpopulation of so-called “drug-tolerant persister cells” (DTPs). A hallmark of the persister state is reversibility upon withdrawal of drug, resulting in re-establishment of a mixed population of sensitive and drug-tolerant cells.CC BY · PubMed Central
Figure 3 Studying persisters in cancer. (A) Modeling persisters using in vitro cell culture systems. Persisters are modeled by a sub-population of cells that remain viable in culture upon extended drug treatment after the majority of sensitive parental cells are eliminated. PC9 EGFR-mutant lung cancer cells are shown before (left) and during gefitinib treatment. Over time, the population of drug-tolerant persisters (middle images) gives rise to a fully resistant T790M+ clone (right image). (B) Modeling persisters in vivo using mouse xenograft tumors. Drug treatment leads to tumor regression followed by a period of stable “minimal residual disease” (MRD) in which a small population of cancer cells exist within tumors that are no longer regressing. Shown are H&E images of EGFR-mutant lung cancer patient-derived xenograft tumors before or after treatment with osimertinib, revealing small residual clusters of surviving tumor cells. (C) Studying persisters in the clinic. As illustrated by a typical waterfall plot of best tumor response, most patients do not experience complete responses to targeted therapies. Residual disease lesions harbor surviving cancer cells but may remain stable for months or even years. Sequential pre/on-treatment and progression biopsies enable study of persister phenotypes and the evolutionary trajectories of resistant cancer cells. H&E images depict sequential biopsies from an EGFR lung cancer patient treated with EGFR targeted therapy in a clinical trial. In the on-treatment biopsy, small clusters of tumors cells are surrounded by extensive fibroblastic stroma.
Figure 3 Studying persisters in cancer. (A) Modeling persisters using in vitro cell culture systems. Persisters are modeled by a sub-population of cells that remain viable in culture upon extended drug treatment after the majority of sensitive parental cells are eliminated. PC9 EGFR-mutant lung cancer cells are shown before (left) and during gefitinib treatment. Over time, the population of drug-tolerant persisters (middle images) gives rise to a fully resistant T790M+ clone (right image). (B) Modeling persisters in vivo using mouse xenograft tumors. Drug treatment leads to tumor regression followed by a period of stable “minimal residual disease” (MRD) in which a small population of cancer cells exist within tumors that are no longer regressing. Shown are H&E images of EGFR-mutant lung cancer patient-derived xenograft tumors before or after treatment with osimertinib, revealing small residual clusters of surviving tumor cells. (C) Studying persisters in the clinic. As illustrated by a typical waterfall plot of best tumor response, most patients do not experience complete responses to targeted therapies. Residual disease lesions harbor surviving cancer cells but may remain stable for months or even years. Sequential pre/on-treatment and progression biopsies enable study of persister phenotypes and the evolutionary trajectories of resistant cancer cells. H&E images depict sequential biopsies from an EGFR lung cancer patient treated with EGFR targeted therapy in a clinical trial. In the on-treatment biopsy, small clusters of tumors cells are surrounded by extensive fibroblastic stroma.CC BY · PubMed Central

Verification

Claims the paper makes

21 Valid · 0 Not valid · 88 Not checked · 30 Own results and interpretations

89 more claims · 13 with their cited sources checked

Create a free account to see all 139 claims and to verify the 73 references still open.

See all claims — free account
  • It may state two separate claims as one. 38
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 131 references

Cited by

See all 196

Metadata

Authors
Cabanos, H. F., & Hata, A. N.
Affiliations
Harvard University (US)
Corresponding author
Hata, Aaron N.
Venue
Cancers
Publisher
MDPI AG
Published
2021-05-28
Volume
13
Issue
11
Pages
2666
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3164747206
Cited by
189
References
131
Citations by year
2026: 24 · 2025: 37 · 2024: 58 · 2023: 43 · 2022: 25 · 2021: 2
FWCI
4.03
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health (K08 CA197389, R01 CA137008)
  • Doris Duke Charitable Foundation (Clinical Scientist Development Award)
  • Stand Up To Cancer (Convergence 1.0 Team Award)
  • V Foundation (Scholar Award)
  • Ludwig Center at Harvard (N/A)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords
drug-tolerant persister cells, targeted therapy, drug resistance, minimal residual disease, lung cancer, tumor dormancy, tumor recurrence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. https://app.cochat.ai/papers/10.3390/cancers13112666
The paper
Cabanos, H. F., & Hata, A. N. (2021). Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers. https://doi.org/10.3390/cancers13112666

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.